Besides this distinction, doctor Xavier Bosch has also received recently from American Society for Colposcopy and Cervical Pathology - ASCCP the award: "Distinguished Scientific Achievement Award" for his contribution to the advances in the knowledge of epidemiology of cervical cancer, how the illness progresses, clinic evaluation and treatment of women affected by the pathologies associated to the Virus of Human Papiloma. This prize is the highest rank of those awarded by ASCCP. We would also like to mention the “Distinguished Service Award” given by the European Research Organization on Genital Infection and Neoplasia – EUROGIN for his scientific career and his contribution to the fight against cervial cancer.

Cervical cancer is the most frequent among feminine population, and the first cause of premature death among the women in poor countries. The Service of Epidemiology and cancer register of ICO, led by Dr. Xavier Bosch, has researched into and evaluated the efficacy of this new vaccine, which foresees the infection by the virus of human papiloma, a virus of sexual transmission that causes 90% of the cases of cervical cancer, according to research coordinated by Dr. Bosch. Precisaly, this month of June the U.S.A. have authorized the vaccine to prevent cervial cancer, which is expected to be commercialised in Spain within a year.